Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR.
スポンサーリンク
概要
- 論文の詳細を見る
CS-905 is a potent dihydropyridine calcium blocker that has a gradual and long-lasting antihypertensive action with little tachycardia in SHR. In this study, we investigated chronic and acute effects of CS-905 on renal functions in SHR. To examine the chronic effects, 23 week-old male SHR were treated with CS-905 (1 or 3 mg/kg/day, p.o.) or 0.3% CMC (carboxymethylcellulose). After the 15 weektreatment, the agent dose-relatedly lowered systolic blood pressure measured 24 hr after the final administration (184±2 and 173±3 mmHg at 1 and 3 mg/kg/day vs. 218±4 mmHg for the control group). Natriuresis and the reduction of urinary protein excretion were also observed in the CS-905 treated groups. Urinary NAG (N-acetyl-β-D-glucosaminidase) activity tended to decrease, but not significantly. Histopathological changes observed in the SHR kidney were reduced by chronic treatment with CS-905. On a single oral administration in 38 week-old SHR, CS-905 caused natriuresis at a dose of 3 mg/kg, but did not affect urinary protein excretion and urinary NAG activity. These effects of CS-905 on renal functions may be beneficial in the treatment of hypertension.
- 公益社団法人 日本薬理学会の論文
著者
-
MIYAMOTO Masaaki
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
KOIKE Hiroyuki
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
OIZUMI Kiyoshi
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
NISHINO Hiroshi
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
FUKUSHIGE Junichiro
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
FUKAMI Masaharu
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
KOIKE Hiroyuki
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
関連論文
- Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR.
- Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.
- Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
- Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR.